Stock Analysis
Abbott LaboratoriesABT
P/E 33.46×· 5Y range 12.74–42.50×· 69th percentile of history
Sector: Healthcare · Industry: Medical Devices
AnalystsStrong Buy33 analystsP/E 33.5× sits at the 69th percentile of its 5.089664613278576-year history.
Cash covers 17% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality87
- Financial Health60
Risks
- Growth31
Mixed picture — no clear quality or value edge.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Interest coverage 9.8× — debt well covered
What's happening with ABT
Profile
Strong earnings quality; growth and valuation lag behind.
How is each axis scored?
- Valuation42/100 · Weak
- P/E vs own history (69th pct)5/25
- FCF yield (4.3%)12/25
- P/S (3.9x)20/25
- EV/EBIT (28.2x)5/25
- Growth31/100 · Weak
- Revenue CAGR (0.7%)6/25
- Net income CAGR (-2.0%)0/25
- EPS CAGR 5Y (-1.4%)0/25
- Fwd implied growth (89.2%)25/25
- Profitability57/100 · Moderate
- ROIC (7.4%)5/25
- ROE (10.5%)12/25
- Net margin (11.6%)20/25
- Operating margin (15.8%)20/25
- Financial Health60/100 · Moderate
- Altman Z (2.92)18/25
- Current ratio (1.38)12/25
- Interest coverage (9.8x)18/25
- Net cash / debt (D/A 25%)12/25
- Quality87/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.49)20/25
- FCF conversion (144%)25/25
- Margin stability (σ 5.3%)20/25
- Moat62/100 · Moderate
- ROIC >12% years (2/10 yrs)0/25
- Median gross margin (56.5%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 1.7%)12/25
About Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Show more
Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Headquarters: ABBOTT PARK, IL · Employees: 115,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
42D+P/E (TTM)33.2xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 12.7x–42.5x · 69th pct
P/FCF23.2xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.3%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.1%–5.1% · 75th pct
P/S (TTM)3.87xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.2x–6.0x · 10th pct
EV/EBIT28.2xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 17.8x–37.3x · 46th pct
EV/Sales4.5xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E17.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.48xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.56D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.35%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio78.5%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
57CROIC7.4%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE10.5%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA5.6%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin11.6%A
Grade A: HighNet Income / Revenue
Operating Margin15.8%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin56.6%A
Grade A: PremiumGross Profit / Revenue
FCF Margin16.8%A
Grade A: HighFCF / Revenue
True FCF Margin15.3%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR0.7%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-2.0%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-1.4%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth89.2%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-3.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income13.2%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.5%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
60BAltman Z-Score2.92C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.38xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.80xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage9.8xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.5yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT3.7xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.63xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.17xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
87APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.49A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion144.2%A
Grade A: StrongFCF / Net Income
Margin Stability5.3%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue4.5%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.48xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Gonzalez Patricia Paola Filed | Gonzalez Patricia Paola | Grant / award | +333 | |
Ahuja Nita Filed | Ahuja Nita | Grant / award | +318 | |
Roman Michael F Filed | Roman Michael F | Grant / award | +381 | |
Stratton John G Filed | Stratton John G | Grant / award | +397 | |
Conroy Kevin T Filed | Conroy Kevin T | Grant / award | +318 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Conroy Kevin T Filed | Conroy Kevin T | Tax withholding | -52507 | |
MCCOY JOHN A. JR. Filed | MCCOY JOHN A. JR. | SellOpen market sale | -27 | |
Boudreau Philip P Filed | Boudreau Philip P | Tax withholding | -388 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
62BROIC >12% Years2/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)56.5%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor1.7%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.14
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.24
Cash & short-term investments per share (Finnhub)
Book Value / Share$29.54
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$32.72B
Total debt obligations (short + long term)
Cash & Equiv.$5.60B
Cash and short-term investments
Net Debt$27.12B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$51.76B
Shareholders' equity (book value)
Asset / Liability1.90xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$180.18B
Current Market Capitalization
Beta0.55B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Abbott Laboratories (ABT)
Abbott Laboratories meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.92 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.49 suggests a low likelihood of earnings manipulation. Abbott Laboratories converts about 17% of revenue into free cash flow — strong cash generation.
- Takes ~3.5 years to repay net debt from free cash flow.
- The stock currently yields 2.4% in dividends.
- Abbott Laboratories reports earnings in 5 days — a potential volatility catalyst.
See how ABT ranks on the Capex Tracker — top 50 capital spenders compared.
Earnings
View earnings calendar →Next Earnings
| Date | Time | EPS Est. | Rev Est. |
|---|---|---|---|
| Oct 21, 2026 | After-Hrs | $1.43 | $13.1B |
Recent Market Moves
See all ABT moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 12 | Regular | 102.03 | +2.44% | 2.08 |
| Oct 5 | Regular | 100.41 | +2.98% | 3.05 |
| Oct 5 | After-hours | 100.64 | +3.22% | 3.26 |
Frequently Asked Questions about ABT
What is the current Abbott Laboratories (ABT) stock price?
ABT is trading at $104.89 at the last market close, up 0.20% on the session. PreMarketPrice tracks ABT pre-market, intraday and after-hours prices.
Is ABT stock a buy right now?
PreMarketPrice's quantitative model rates Abbott Laboratories's financial health at 60/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ABT stock overvalued?
Abbott Laboratories trades at a trailing P/E of 33.2 and our valuation score rates it 42/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Abbott Laboratories report earnings?
ABT is scheduled to report on 2026-10-21 (in 5 days). Check the Earnings section for recent results and the full calendar.
What sector does Abbott Laboratories operate in?
Abbott Laboratories operates in the Healthcare sector, within the Medical Devices industry. The Related Stocks section lists sector peers for comparison.
What does Abbott Laboratories do?
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs.
About Abbott Laboratories (ABT) Stock
Abbott Laboratories (ABT) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry. As of the latest update, Abbott Laboratories is trading at $104.89, up 0.20% on the day with a market capitalization of $180.2 billion. The financial health score for ABT is 60/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ABT stock.
ABT Stock Analysis & Key Metrics
On PreMarketPrice, you can track Abbott Laboratories (ABT) across multiple dimensions:
- Pre-market price & movement: Real-time ABT stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Earnings calendar: Upcoming and past earnings reports for ABT, including EPS estimates, actual results, and surprise percentages.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ABT with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Abbott Laboratories across multiple reporting periods.
- Financial health score: A composite score of 60/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ABT.
- Sector peers: Compare ABT against 6 other healthcare stocks on key financial metrics.
Is ABT a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Abbott Laboratories (ABT) as an investment. The financial health score of 60/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average. Earnings data reveals whether the company is meeting or beating analyst expectations.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Abbott Laboratories (ABT) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.